David Y Lee1, Kelly T Huynh1, Annabelle Teng2, Briana J Lau1, Sarah Vitug3, Ji-Hey Lee4, Stacey L Stern4, Leland J Foshag1, Mark B Faries5. 1. Department of Surgical Oncology, The John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, CA, USA. 2. Department of Surgery, Mount Sinai, St-Luke's-Roosevelt Hospital Center, New York, NY, USA. 3. Ochsner Clinical School, University of Queensland School of Medicine, Saint Lucia, QLD, Australia. 4. Department of Biostatistics, The John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, CA, USA. 5. Department of Surgical Oncology, The John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, CA, USA. mark.faries@jwci.org.
Abstract
BACKGROUND: The status of the sentinel lymph node in melanoma is an important prognostic factor. The clinical predictors and implications of false-negative (FN) biopsy remain debatable. METHODS: We compared patients with positive sentinel lymph node biopsy (SNB) [true positive (TP)] and negative SNB with and without regional recurrence [FN, true negative (TN)] from our prospective institutional database. RESULTS: Among 2986 patients (84 FN, 494 TP, and 2408 TN; median follow-up 93 months), the incidence of FN-SNB was 2.8%. While calculated FN rate was 14.5% [84 FN/(494 TP + 84 FN) × 100], when we accounted for local/in-transit recurrence (LITR) this rate was 8.5% [46 FN/(494 TP + 46 FN) × 100 %]. On multivariate analysis, male gender (OR 2.0, 95% CI 1.1-3.6, p = 0.018), head/neck primaries (OR 2.5, 95% CI 1.3-4.8, p < 0.006), and LITR (OR 3.5, 95% CI 2.1-5.8, p < 0.001) were associated with FN-SNB. Melanoma-specific survival (MSS) for the FN group was similar to the TP group at 5 years (68 vs. 73%, p = 0.539). However, MSS declined more for the FN group with a longer follow up and was significantly worse at 10 years (44 vs. 64%, p < 0.001). On multivariate analysis, FN-SNB was a significant predictor of worse MSS in melanomas <4 mm in Breslow thickness (HR 1.6; 95% CI 1.1-2.5, p = 0.021). CONCLUSIONS: Male gender, LITR, and head and neck tumors were associated with FN-SNB. FN-SNB was an independent predictor of worse MSS in melanomas <4 mm in thickness, but this survival difference did not become apparent until after 5 years of follow-up.
BACKGROUND: The status of the sentinel lymph node in melanoma is an important prognostic factor. The clinical predictors and implications of false-negative (FN) biopsy remain debatable. METHODS: We compared patients with positive sentinel lymph node biopsy (SNB) [true positive (TP)] and negative SNB with and without regional recurrence [FN, true negative (TN)] from our prospective institutional database. RESULTS: Among 2986 patients (84 FN, 494 TP, and 2408 TN; median follow-up 93 months), the incidence of FN-SNB was 2.8%. While calculated FN rate was 14.5% [84 FN/(494 TP + 84 FN) × 100], when we accounted for local/in-transit recurrence (LITR) this rate was 8.5% [46 FN/(494 TP + 46 FN) × 100 %]. On multivariate analysis, male gender (OR 2.0, 95% CI 1.1-3.6, p = 0.018), head/neck primaries (OR 2.5, 95% CI 1.3-4.8, p < 0.006), and LITR (OR 3.5, 95% CI 2.1-5.8, p < 0.001) were associated with FN-SNB. Melanoma-specific survival (MSS) for the FN group was similar to the TP group at 5 years (68 vs. 73%, p = 0.539). However, MSS declined more for the FN group with a longer follow up and was significantly worse at 10 years (44 vs. 64%, p < 0.001). On multivariate analysis, FN-SNB was a significant predictor of worse MSS in melanomas <4 mm in Breslow thickness (HR 1.6; 95% CI 1.1-2.5, p = 0.021). CONCLUSIONS: Male gender, LITR, and head and neck tumors were associated with FN-SNB. FN-SNB was an independent predictor of worse MSS in melanomas <4 mm in thickness, but this survival difference did not become apparent until after 5 years of follow-up.
Authors: Charles R Scoggins; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; Michael J Edwards; Anees B Chagpar; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters Journal: Ann Surg Date: 2006-05 Impact factor: 12.969
Authors: Rooshdiya Z Karim; Richard A Scolyer; Wei Li; Vivian S K Yee; J Gregory McKinnon; Ling-Xi L Li; Roger F Uren; Stella Lam; Alison Beavis; Michael Dawson; Philip Doble; Dave S B Hoon; John F Thompson Journal: Ann Surg Date: 2008-06 Impact factor: 12.969
Authors: Zbigniew I Nowecki; Piotr Rutkowski; Anna Nasierowska-Guttmejer; Wlodzimierz Ruka Journal: Ann Surg Oncol Date: 2006-10-03 Impact factor: 5.344
Authors: Edward L Jones; Teresa S Jones; Nathan W Pearlman; Dexiang Gao; Robert Stovall; Csaba Gajdos; Nicole Kounalakis; Rene Gonzalez; Karl D Lewis; William A Robinson; Martin D McCarter Journal: JAMA Surg Date: 2013-05 Impact factor: 14.766
Authors: Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries Journal: N Engl J Med Date: 2014-02-13 Impact factor: 91.245
Authors: J E Gershenwald; M I Colome; J E Lee; P F Mansfield; C Tseng; J J Lee; C M Balch; M I Ross Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: Timothy R Fincher; John C O'Brien; Todd M McCarty; Tammy L Fisher; John T Preskitt; Zelig H Lieberman; Jeffrey F Stephens; Joseph A Kuhn Journal: Arch Otolaryngol Head Neck Surg Date: 2004-07
Authors: Arjen Joosse; Sandra Collette; Stefan Suciu; Tamar Nijsten; Poulam M Patel; Ulrich Keilholz; Alexander M M Eggermont; Jan Willem W Coebergh; Esther de Vries Journal: J Clin Oncol Date: 2013-05-20 Impact factor: 44.544
Authors: Richard J Straker; Michael J Carr; Andrew J Sinnamon; Adrienne B Shannon; James Sun; Karenia Landa; Kirsten M Baecher; Christian Wood; Kevin Lynch; Harrison G Bartels; Robyn Panchaud; Michael C Lowe; Craig L Slingluff; Mark J Jameson; Kenneth Tsai; Mark B Faries; Georgia M Beasley; Vernon Sondak; Giorgos C Karakousis; Jonathan S Zager; John T Miura Journal: Ann Surg Oncol Date: 2021-04-22 Impact factor: 5.344
Authors: Daniel Eiger; Daniel Arcuschin de Oliveira; Renato Leão de Oliveira; Murilo Costa Sousa; Mireille Darc Cavalcante Brandão; Renato Santos de Oliveira Filho Journal: An Bras Dermatol Date: 2018 Jul-Aug Impact factor: 1.896
Authors: Brian R Gastman; Jonathan S Zager; Jane L Messina; Robert W Cook; Kyle R Covington; Brooke Middlebrook; Pedram Gerami; Jeffrey D Wayne; Sancy Leachman; John T Vetto Journal: Head Neck Date: 2019-01-29 Impact factor: 3.147
Authors: Jill C Rubinstein; Gang Han; Laura Jackson; Kaleigh Bulloch; Stephan Ariyan; Deepak Narayan; Bonnie G Rothberg; Dale Han Journal: Cancer Med Date: 2016-09-27 Impact factor: 4.452